{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T22:18:39Z","timestamp":1782425919006,"version":"3.54.5"},"reference-count":144,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cardiovascular diseases (CVDs) remain a significant global health challenge, leading to substantial morbidity and mortality. Despite recent advancements in CVD management, pharmaceutical treatments often suffer from poor pharmacokinetics and high toxicity. With the rapid progress of modern molecular biology and immunology, however, single-chain fragment variable (scFv) molecule engineering has emerged as a promising theranostic tool to offer specificity and versatility in targeting CVD-related antigens. To represent the latest development on the potential of scFv in the context of CVDs, this review summarized the new mechanism of action and applications as therapeutic, as well as diagnostic agents. Furthermore, the advantages of scFv, including its small size, ease of modification, and ability to be engineered for enhanced affinity and specificity, are also described. Finally, such challenges as immunogenicity, stability, and scalability, alongside strategies to overcome these hurdles, are deeply scrutinized to provide safer and more effective strategies for the diagnosis and treatment of the incurable CVDs.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1443290","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T06:22:38Z","timestamp":1734070958000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Single chain fragment variable, a new theranostic approach for cardiovascular diseases"],"prefix":"10.3389","volume":"15","author":[{"given":"Rukhshan","family":"Zahid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juncheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zecheng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Ishtiaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuekang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5334\/gh.1278","article-title":"World Heart Federation roadmap for secondary prevention of cardiovascular disease: 2023 update","volume":"19","author":"Laranjo","year":"2024","journal-title":"Global Heart"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2019-0228","article-title":"Cardiovascular nanomedicine: the route ahead","volume":"14","author":"Iafisco","year":"2019","journal-title":"Future Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S0140-6736(19)32008-2","article-title":"Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study","volume":"395","author":"Yusuf","year":"2020","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the global burden of disease study 2017","volume":"392","author":"Harikrishnan","year":"2018","journal-title":"The Lancet"},{"key":"B5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/978-3-030-56279-3_27","article-title":"Secondary Prevention and Cardiac Rehabilitation","volume-title":"ASPC Manual of Preventive Cardiology","author":"Lo","year":"2021"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.066936","article-title":"Endothelial function and inflammation in coronary artery disease","volume":"84","author":"Tousoulis","year":"2008","journal-title":"Postgraduate Med J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3578","article-title":"Perspectives and opportunities for nanomedicine in the management of atherosclerosis","volume":"10","author":"Lobatto","year":"2011","journal-title":"Nat Rev Drug Discovery"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R800074-JLR200","article-title":"The role of oxidized phospholipids in atherosclerosis","author":"Berliner","year":"2009","journal-title":"J Lipid Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1093\/eurheartj\/ehx146","article-title":"Regulation of oxidized platelet lipidome: implications for coronary artery disease","volume":"38","author":"Chatterjee","year":"2017","journal-title":"Eur Heart J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"9582430","DOI":"10.1155\/2016\/9582430","article-title":"Macrophages and their role in atherosclerosis: pathophysiology and transcriptome analysis","volume":"2016","author":"Bobryshev","year":"2016","journal-title":"BioMed Res Int"},{"key":"B11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12951-021-01047-4","article-title":"An atherosclerotic plaque-targeted single-chain antibody for MR\/NIR-II imaging of atherosclerosis and anti-atherosclerosis therapy","volume":"19","author":"Zhang","year":"2021","journal-title":"J Nanobiotechnology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2000037","DOI":"10.1002\/adma.202000037","article-title":"A non-invasive nanoprobe for in vivo photoacoustic imaging of vulnerable atherosclerotic plaque","volume":"32","author":"Ge","year":"2020","journal-title":"Advanced Materials"},{"key":"B13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1039\/C9NH00291J","article-title":"Biomimetic nanoparticle technology for cardiovascular disease detection and treatment","volume":"5","author":"Park","year":"2020","journal-title":"Nanoscale horizons"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.02.010","article-title":"Association between cholesterol crystals and culprit lesion vulnerability in patients with acute coronary syndrome: an optical coherence tomography study","volume":"247","author":"Dai","year":"2016","journal-title":"Atherosclerosis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1039\/D0BM00196A","article-title":"Applications of inorganic nanoparticles in the diagnosis and therapy of atherosclerosis","volume":"8","author":"Dai","year":"2020","journal-title":"Biomaterials Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01930","article-title":"Chemokine-induced macrophage polarization in inflammatory conditions","volume":"9","author":"Ruytinx","year":"2018","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.999404","article-title":"Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases","volume":"13","author":"Yang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.12138","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"328","author":"Chou","year":"2022","journal-title":"Jama"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2019.04.014","article-title":"Role of beta-blockers in cardiovascular disease in 2019","volume":"72","author":"Martinez-Milla","year":"2019","journal-title":"Rev Espa\u00f1ola Cardiolog\u00eda (English Edition)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pharmthera.2012.04.002","article-title":"Impact of kinins in the treatment of cardiovascular diseases","volume":"135","author":"Regoli","year":"2012","journal-title":"Pharmacol Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-052915-015509","article-title":"Neprilysin inhibitors: emerging therapy for heart failure","volume":"68","author":"Owens","year":"2017","journal-title":"Annu Rev Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"New Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"New Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvad034","article-title":"New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022","volume":"9","author":"Tamargo","year":"2023","journal-title":"Eur Heart J - Cardiovasc Pharmacotherapy"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J Biomed Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198508083130601","article-title":"A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants","volume":"313","year":"1985","journal-title":"New Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbac021","article-title":"The global landscape of approved antibody therapies","volume":"5","author":"Lyu","year":"2022","journal-title":"Antibody Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2168-1","article-title":"Multispecific drugs herald a new era of biopharmaceutical innovation","volume":"580","author":"Deshaies","year":"2020","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg1209","article-title":"Bispecific antibodies","volume":"372","author":"Brinkmann","year":"2021","journal-title":"Science"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6750-7-14","article-title":"Single chain Fab (scFab) fragment","volume":"7","author":"Hust","year":"2007","journal-title":"BMC Biotechnol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.3390\/cancers14174206","article-title":"Single-Chain fragment variable: recent progress in cancer diagnosis and therapy","volume":"14","author":"Mu\u00f1oz-L\u00f3pez","year":"2022","journal-title":"Cancers"},{"key":"B34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/antib2020193","article-title":"In vivo applications of single chain fv (Variable domain) (scFv) fragments","volume":"2","author":"Monnier","year":"2013","journal-title":"Antibodies"},{"key":"B35","article-title":"Radioiodinated anti\u2013TAG-72 non-covalently linked CC49 divalent single-chain Fv antibody","author":"Cheng","year":"2010","journal-title":"Molecular Imaging and Contrast Agent Database (MICAD), National Center for Biotechnology Information (US)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1021\/ac202159p","article-title":"Toward in vivo imaging of heart disease using a radiolabeled single-chain Fv fragment targeting tenascin-C","volume":"83","author":"Kobayashi","year":"2011","journal-title":"Analytical Chem"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0409-331","article-title":"Development trends for therapeutic antibody fragments","volume":"27","author":"Nelson","year":"2009","journal-title":"Nat Biotechnol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2174\/138945009787354502","article-title":"Current constructs and targets in clinical development for antibody-based cancer therapy","volume":"10","author":"Deckert","year":"2009","journal-title":"Curr Drug Targets"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid \u03b2-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.12.007","article-title":"In vivo distribution of single chain variable fragment (scFv) against atherothrombotic oxidized LDL\/\u03b22-glycoprotein I complexes into atherosclerotic plaques of WHHL rabbits: implication for clinical PET imaging","volume":"16","author":"Sasaki","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.962124","article-title":"In vivo Phage Display: A promising selection strategy for the improvement of antibody targeting and drug delivery properties","volume":"13","author":"Andr\u00e9","year":"2022","journal-title":"Front Microbiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.111.249375","article-title":"Enzymatic single-chain antibody tagging: a universal approach to targeted molecular imaging and cell homing in cardiovascular disease","volume":"109","author":"Ta","year":"2011","journal-title":"Circ Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.7150\/thno.19698","article-title":"Platelet-targeted delivery of peripheral blood mononuclear cells to the ischemic heart restores cardiac function after ischemia-reperfusion injury","volume":"7","author":"Ziegler","year":"2017","journal-title":"Theranostics"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.3346.3346","article-title":"Heparin-induced thrombocytopenia and thrombosis: therapeutic strategy using a single-chain variable fragment (scFv) antibody","volume":"120","author":"New","year":"2012","journal-title":"Blood"},{"key":"B45","article-title":"Principles of innate and adaptive immunity","volume-title":"Immunobiology: The Immune System in Health and Disease","author":"Janeway","year":"2001"},{"key":"B46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nri1266","article-title":"Human antibody\u2013Fc receptor interactions illuminated by crystal structures","volume":"4","author":"Woof","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1137","article-title":"Monoclonal antibody therapy of cancer","volume":"23","author":"Adams","year":"2005","journal-title":"Nat Biotechnol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1142","article-title":"Engineered antibody fragments and the rise of single domains","volume":"23","author":"Holliger","year":"2005","journal-title":"Nat Biotechnol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1042\/bj0730119","article-title":"The hydrolysis of rabbit \u03b3-globulin and antibodies with crystalline papain","volume":"73","author":"Porter","year":"1959","journal-title":"Biochem J"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/science.3285470","article-title":"Assembly of a functional immunoglobulin Fv fragment in Escherichia coli","volume":"240","author":"Skerra","year":"1988","journal-title":"Science"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(00)01668-6","article-title":"Of mice and men: hybridoma and recombinant antibodies","volume":"21","author":"Little","year":"2000","journal-title":"Immunol Today"},{"key":"B52","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0958-1669(98)80014-1","article-title":"Recombinant antibody fragments","volume":"9","author":"Hudson","year":"1998","journal-title":"Curr Opin Biotechnol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-012-4632-9","article-title":"Production and characterization of a CD25-specific scFv-Fc antibody secreted from Pichia pastoris","volume":"97","author":"Wan","year":"2013","journal-title":"Appl Microbiol Biotechnol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1039\/C0MB00154F","article-title":"Enhancing the thermal stability of a single-chain Fv fragment by in vivo global fluorination of the proline residues","volume":"7","author":"Edwardraja","year":"2011","journal-title":"Mol Biosyst"},{"key":"B55","doi-asserted-by":"crossref","DOI":"10.4161\/mabs.2.1.10786","article-title":"Antibody fragments: hope and hype","volume-title":"MAbs","author":"Nelson","year":"2010"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1126\/science.3140379","article-title":"Single-chain antigen-binding proteins","volume":"242","author":"Bird","year":"1988","journal-title":"Science"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S0958-1669(98)80092-X","article-title":"Strategies for selection of antibodies by phage display","volume":"9","author":"Griffiths","year":"1998","journal-title":"Curr Opin Biotechnol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/0022-2836(90)90085-Z","article-title":"An investigation of oligopeptides linking domains in protein tertiary structures and possible candidates for general gene fusion","volume":"211","author":"Argos","year":"1990","journal-title":"J Mol Biol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"980250","DOI":"10.1155\/2012\/980250","article-title":"scFv antibody: principles and clinical application","volume":"2012","author":"Ahmad","year":"2012","journal-title":"J Immunol Res"},{"key":"B60","first-page":"46","article-title":"[3] Protein engineering of single-chain Fv analogs and fusion proteins","volume-title":"Methods in enzymology","author":"Huston","year":"1991"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/12.7.623","article-title":"Synthesis, cloning and expression of the single-chain Fv gene of the HPr-specific monoclonal antibody, Jel42. Determination of binding constants with wild-type and mutant HPrs","volume":"12","author":"Smallshaw","year":"1999","journal-title":"Protein Eng"},{"key":"B62","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcdb.2009.01.010","article-title":"Antibody production, design and use for biosensor-based applications","volume-title":"Seminars in Cell & Developmental Biology","author":"Conroy","year":"2009"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/6.8.989","article-title":"An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability","volume":"6","author":"Whitlow","year":"1993","journal-title":"Protein Engineering Design Selection"},{"key":"B64","article-title":"Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins","volume":"2","author":"Reiter","year":"1996","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2005.04.015","article-title":"Production, purification, and characterization of human scFv antibodies expressed in Saccharomyces cerevisiae, Pichia pastoris, and Escherichia coli","volume":"42","author":"Miller","year":"2005","journal-title":"Protein Expression purification"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.3390\/biomedicines11061610","article-title":"Mechanisms of action and limitations of monoclonal antibodies and single chain fragment variable (scFv) in the treatment of cancer","volume":"11","author":"Rodr\u00edguez-Nava","year":"2023","journal-title":"Biomedicines"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12896-018-0466-6","article-title":"A novel synthetic trivalent single chain variable fragment (tri-scFv) construction platform based on the SpyTag\/SpyCatcher protein ligase system","volume":"18","author":"Alam","year":"2018","journal-title":"BMC Biotechnol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discovery Today"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(99)00157-X","article-title":"High avidity scFv multimers; diabodies and triabodies","volume":"231","author":"Hudson","year":"1999","journal-title":"J Immunol Methods"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(03)00251-5","article-title":"Di-diabody: a novel tetravalent bispecific antibody molecule by design","volume":"279","author":"Lu","year":"2003","journal-title":"J Immunol Methods"},{"key":"B71","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0022-1759(00)00342-2","article-title":"Design and application of diabodies, triabodies and tetrabodies for cancer targeting","volume":"248","author":"Todorovska","year":"2001","journal-title":"J Immunol Methods"},{"key":"B72","article-title":"Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts","volume":"56","author":"Hu","year":"1996","journal-title":"Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-992-5_20","article-title":"Reformatting of scFv antibodies into the scFv-Fc format and their downstream purification","author":"Bujak","year":"2014","journal-title":"Monoclonal Antibodies: Methods Protoc"},{"key":"B74","doi-asserted-by":"publisher","first-page":"6.9. 1","DOI":"10.1002\/0471140864.2009.55.issue-1","article-title":"Overview on concepts and applications of Fab antibody fragments","volume":"55","author":"Rader","year":"2009","journal-title":"Curr Protoc Protein Sci"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5385-08.2009","article-title":"Sustained in vivo inhibition of protein domains using single-chain Fv recombinant antibodies and its application to dissect RGMa activity on axonal outgrowth","volume":"29","author":"Tassew","year":"2009","journal-title":"J Neurosci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1791","article-title":"Beyond natural antibodies: the power of in vitro display technologies","volume":"29","author":"Bradbury","year":"2011","journal-title":"Nat Biotechnol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1039\/D0BM01903H","article-title":"Single chain variable fragment fused to maltose binding protein: a modular nanocarrier platform for the targeted delivery of antitumorals","volume":"9","author":"Reche-Perez","year":"2021","journal-title":"Biomaterials Sci"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.83670-0","article-title":"Delivery of single-chain antibodies (scFvs) directed against the 37\/67 kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy","volume":"89","author":"Zuber","year":"2008","journal-title":"J Gen Virol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016287","article-title":"In vivo human single-chain fragment variable phage display-assisted identification of galectin-3 as a new biomarker of atherosclerosis","volume":"10","author":"Hemadou","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2011.06.012","article-title":"Strategies for extended serum half-life of protein therapeutics","volume":"22","author":"Kontermann","year":"2011","journal-title":"Curr Opin Biotechnol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2016.00043","article-title":"Use of single-chain antibody derivatives for targeted drug delivery","volume":"22","author":"Safdari","year":"2016","journal-title":"Mol Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.2.669","article-title":"Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity","volume":"95","author":"Chowdhury","year":"1998","journal-title":"Proc Natl Acad Sci"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2017.09.010","article-title":"Iron oxide core oil-in-water nanoemulsion as tracer for atherosclerosis MPI and MRI imaging","volume":"532","author":"Pr\u00e9vot","year":"2017","journal-title":"Int J Pharmaceutics"},{"key":"B84","doi-asserted-by":"publisher","first-page":"187621","DOI":"10.1155\/2010\/187621","article-title":"Research article A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model","volume":"2010","author":"Gattenl\u00f6hner","year":"2010","journal-title":"Journal of biomedicine & biotechnology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"459676","DOI":"10.1155\/2014\/459676","article-title":"Biological evaluation of 131 I-and CF750-labeled Dmab (scFv)-Fc antibodies for xenograft imaging of CD25-positive tumors","volume":"2014","author":"Fan","year":"2014","journal-title":"BioMed Res Int"},{"key":"B86","article-title":"Single-chain fv radioimmunotargeting","volume":"40","author":"Huston","year":"1996","journal-title":"Q J Nucl medicine: Off Publ Ital Assoc Nucl Med (AIMN)[and] Int Assoc Radiopharmacology (IAR)"},{"key":"B87","doi-asserted-by":"publisher","first-page":"105009","DOI":"10.1016\/j.jddst.2023.105009","article-title":"Recombinant antibody fragment therapeutics: Current status and future prospects of scFv, nanobody, and mimotopes","volume":"89","author":"Ghaderi","year":"2023","journal-title":"J Drug Delivery Sci Technol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1804038","DOI":"10.1155\/2024\/1804038","article-title":"The potential of single-chain variable fragment antibody: role in future therapeutic and diagnostic biologics","volume":"2024","author":"Gezehagn Kussia","year":"2024","journal-title":"J Immunol Res"},{"key":"B89","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-0716-1450-1","volume-title":"Therapeutic Antibodies: Methods and Protocols","author":"Houen","year":"2022"},{"key":"B90","doi-asserted-by":"publisher","first-page":"102082","DOI":"10.1016\/j.nano.2019.102082","article-title":"Multimodal molecular imaging of atherosclerosis: Nanoparticles functionalized with scFv fragments of an anti-\u03b1IIb\u03b23 antibody","volume":"22","author":"Larivi\u00e8re","year":"2019","journal-title":"Nanomedicine: Nanotechnology Biol Med"},{"key":"B91","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.3390\/ijms22105188","article-title":"A nano-emulsion platform functionalized with a fully human scFv-Fc antibody for atheroma targeting: towards a theranostic approach to atherosclerosis","volume":"22","author":"Bonnet","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.dib.2017.10.058","article-title":"Data on atherosclerosis specific antibody conjugation to nanoemulsions","volume":"15","author":"Pr\u00e9vot","year":"2017","journal-title":"Data Brief"},{"key":"B93","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s00395-007-0652-5","article-title":"ED-B fibronectin (ED-B) can be targeted using a novel single chain antibody conjugate and is associated with macrophage accumulation in atherosclerotic lesions","volume":"102","author":"Dietrich","year":"2007","journal-title":"Basic Res Cardiol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.030312","article-title":"Novel single-chain antibody-targeted microbubbles for molecular ultrasound imaging of thrombosis","volume":"125","author":"Leitner","year":"2012","journal-title":"Circulation"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2012.02.013","article-title":"In vivo phage display to identify new human antibody fragments homing to atherosclerotic endothelial and subendothelial tissues [corrected","volume":"180","author":"Deramchia","year":"2012","journal-title":"Am J Pathol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.25859","article-title":"Cloning and expression of an anti-LDL(-) single-chain variable fragment, and its inhibitory effect on experimental atherosclerosis","volume":"5","author":"Kazuma","year":"2013","journal-title":"mAbs"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0198-8","article-title":"Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice","volume":"558","author":"Que","year":"2018","journal-title":"Nature"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.02.010","article-title":"Dual-targeted theranostic delivery of miRs arrests abdominal aortic aneurysm development","volume":"26","author":"Wang","year":"2018","journal-title":"Mol Ther"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.7150\/thno.14514","article-title":"Thrombus-targeted theranostic microbubbles: A new technology towards concurrent rapid ultrasound diagnosis and bleeding-free fibrinolytic treatment of thrombosis","volume":"6","author":"Wang","year":"2016","journal-title":"Theranostics"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.09.005","article-title":"SPECT and fluorescence imaging of vulnerable atherosclerotic plaque with a vascular cell adhesion molecule 1 single-chain antibody fragment","volume":"254","author":"Liu","year":"2016","journal-title":"Atherosclerosis"},{"key":"B101","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3390\/cells9030583","article-title":"Electronegative LDL promotes inflammation and triglyceride accumulation in macrophages","volume":"9","author":"Puig","year":"2020","journal-title":"Cells"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.1935","article-title":"GFP-SCFV: expression and possible applications as a tool for experimental investigations of atherosclerosis","volume":"30","author":"Faulin Tdo","year":"2014","journal-title":"Biotechnol Prog"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-014-1392-5","article-title":"New strategy to surface functionalization of polymeric nanoparticles: one-pot synthesis of scFv anti-LDL(\u2013)-functionalized nanocapsules","volume":"31","author":"Bender","year":"2014","journal-title":"Pharm Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M609344200","article-title":"Identification of human scFvs targeting atherosclerotic lesions: selection by single round in vivo phage display","volume":"281","author":"Robert","year":"2006","journal-title":"J Biol Chem"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3390\/ijms13066902","article-title":"By-passing large screening experiments using sequencing as a tool to identify scFv fragments targeting atherosclerotic lesions in a novel in vivo phage display selection","volume":"13","author":"Deramchia","year":"2012","journal-title":"Int J Mol Sci"},{"key":"B106","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1038\/s41598-018-33382-2","article-title":"An innovative flow cytometry method to screen human scFv-phages selected by in vivo phage-display in an animal model of atherosclerosis","volume":"8","author":"Hemadou","year":"2018","journal-title":"Sci Rep"},{"key":"B107","doi-asserted-by":"publisher","first-page":"8946935","DOI":"10.1155\/2017\/8946935","article-title":"Improved scFv anti-LOX-1 binding activity by fusion with LOX-1-binding peptides","volume":"2017","author":"Hu","year":"2017","journal-title":"BioMed Res Int"},{"key":"B108","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.devcel.2019.05.026","article-title":"Multimerization and retention of the scavenger receptor SR-B1 in the plasma membrane","volume":"50","author":"Marques","year":"2019","journal-title":"Dev Cell"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2015.11.020","article-title":"Identification and analysis of anti-HDL scFv-antibodies obtained from phage display based synthetic antibody library","volume":"49","author":"Negi","year":"2016","journal-title":"Clin Biochem"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170305","article-title":"A Recombinant Human Anti-Platelet scFv Antibody Produced in Pichia pastoris for Atheroma Targeting","volume":"12","author":"Vallet-Courbin","year":"2017","journal-title":"PloS One"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.731315","article-title":"Complement inhibition targeted to injury specific neoepitopes attenuates atherogenesis in mice","volume":"8","author":"Dai","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.07.017","article-title":"Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression","volume":"58","author":"Tsimikas","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1161\/atvb.42.suppl_1.128","article-title":"Abstract 128: A chimeric antigen receptor targeting MDA-LDL activates regulatory T cells in the presence of human atherosclerotic plaque","volume":"42","author":"Shaligram","year":"2022","journal-title":"Arteriosclerosis Thrombosis Vasc Biol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2016.07.002","article-title":"A nanoformulation containing a scFv reactive to electronegative LDL inhibits atherosclerosis in LDL receptor knockout mice","volume":"107","author":"Cavalcante","year":"2016","journal-title":"Eur J Pharmaceutics Biopharmaceutics"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.652137","article-title":"scFv-anti-LDL(-)-metal-complex multi-wall functionalized-nanocapsules as a promising tool for the prevention of atherosclerosis progression","volume":"8","author":"Cavalcante","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvy136","article-title":"Reduction of myocardial ischaemia\u2013reperfusion injury by inactivating oxidized phospholipids","volume":"115","author":"Yeang","year":"2019","journal-title":"Cardiovasc Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.056414","article-title":"Oxidized phospholipids promote NETosis and arterial thrombosis in LNK(SH2B3) deficiency","volume":"144","author":"Dou","year":"2021","journal-title":"Circulation"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.119.312771","article-title":"Novel autoimmune igM antibody attenuates atherosclerosis in igM deficient low-fat diet-Fed, but not western diet-Fed apoe\u2013\/\u2013mice","volume":"40","author":"Cherepanova","year":"2020","journal-title":"Arteriosclerosis Thrombosis Vasc Biol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.10.10","article-title":"A humanized anti fc\u03b3RIIa scfv inhibits platelet activation, aggregation and thrombus formation in heparin-induced thrombocytopenia (HIT)","volume":"126","author":"Perdomo","year":"2015","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","first-page":"109100","DOI":"10.1016\/j.intimp.2022.109100","article-title":"Collagen VI antibody reduces atherosclerosis by activating monocyte\/macrophage polarization in ApoE\u2013\/\u2013 mice","volume":"111","author":"Liu","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195657","article-title":"DEC205-DC targeted DNA vaccine against CX3CR1 protects against atherogenesis in mice","volume":"13","author":"Zhou","year":"2018","journal-title":"PloS One"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1160\/TH08-12-0816","article-title":"Single-chain antibodies as diagnostic tools and therapeutic agents","volume":"101","author":"Hagemeyer","year":"2009","journal-title":"Thromb haemostasis"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.13092","article-title":"Treatment of atherosclerotic plaque: perspectives on theranostics","volume":"71","author":"Zhang","year":"2019","journal-title":"J Pharm Pharmacol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12951-022-01279-y","article-title":"Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis","volume":"20","author":"Liu","year":"2022","journal-title":"J Nanobiotechnology"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.8.3576","article-title":"In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library","volume":"89","author":"Gram","year":"1992","journal-title":"Proc Natl Acad Sci"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1126","article-title":"Selecting and screening recombinant antibody libraries","volume":"23","author":"Hoogenboom","year":"2005","journal-title":"Nat Biotechnol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nri.2016.67","article-title":"Combinatorial antibody libraries: new advances, new immunological insights","volume":"16","author":"Lerner","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2008.07.013","article-title":"In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification","volume":"46","author":"Steidl","year":"2008","journal-title":"Mol Immunol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.3390\/molecules24142620","article-title":"Cyclization of single-chain fv antibodies markedly suppressed their characteristic aggregation mediated by inter-chain VH-VL interactions","volume":"24","author":"Yamauchi","year":"2019","journal-title":"Molecules"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.9b00367","article-title":"Arginine to lysine mutations increase the aggregation stability of a single-chain variable fragment through unfolded-state interactions","volume":"58","author":"Austerberry","year":"2019","journal-title":"Biochemistry"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.7b09268","article-title":"Decomposing dynamical couplings in mutated scFv antibody fragments into stabilizing and destabilizing effects","volume":"139","author":"Ettayapuram Ramaprasad","year":"2017","journal-title":"J Am Chem Soc"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1182409","article-title":"Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1157","article-title":"Recent advances in stealth coating of nanoparticle drug delivery systems","volume":"4","author":"Amoozgar","year":"2012","journal-title":"Wiley Interdiscip Reviews: Nanomedicine Nanobiotechnology"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiotec.2012.07.011","article-title":"Production of single chain fragment variable (scFv) antibodies in Escherichia coli using the LEX\u2122 bioreactor","volume":"163","author":"Miethe","year":"2013","journal-title":"J Biotechnol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2014.07.007","article-title":"Site-specific immobilization of recombinant antibody fragments through material-binding peptides for the sensitive detection of antigens in enzyme immunoassays","volume":"1844","author":"Kumada","year":"2014","journal-title":"Biochim Biophys Acta (BBA) - Proteins Proteomics"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.3390\/biom13101508","article-title":"Development of an anti-HER2 single-chain variable antibody fragment construct for high-yield soluble expression in escherichia coli and one-step chromatographic purification","volume":"13","author":"Byun","year":"2023","journal-title":"Biomolecules"},{"key":"B137","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40364-021-00332-6","article-title":"A comprehensive comparison between camelid nanobodies and single chain variable fragments","volume":"9","author":"Asaadi","year":"2021","journal-title":"biomark Res"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2015.0036","article-title":"Design and generation of humanized single-chain Fv derived from mouse hybridoma for potential targeting application","volume":"34","author":"Khantasup","year":"2015","journal-title":"Monoclonal Antibodies Immunodiagnosis Immunotherapy"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006301519427","article-title":"Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies","volume":"42","author":"St\u00f6ger","year":"2000","journal-title":"Plant Mol Biol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2993-2","article-title":"ALDH4A1 is an atherosclerosis auto-antigen targeted by protective antibodies","volume":"589","author":"Lorenzo","year":"2021","journal-title":"Nature"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab631","article-title":"Matrix metalloproteinase-2 on activated platelets triggers endothelial PAR-1 initiating atherosclerosis","volume":"43","author":"Momi","year":"2021","journal-title":"Eur Heart J"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9259","article-title":"Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice","volume":"105","author":"Febbraio","year":"2000","journal-title":"J Clin Invest"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1000760","article-title":"Annexins and cardiovascular diseases: Beyond membrane trafficking and repair","volume":"10","author":"M\u00e9ndez-Barbero","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.8.4036","article-title":"Soluble fibrinogen-like protein 2\/fibroleukin exhibits immunosuppressive properties: suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells","volume":"170","author":"Chan","year":"2003","journal-title":"J Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1443290\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T06:22:45Z","timestamp":1734070965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1443290\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":144,"alternative-id":["10.3389\/fimmu.2024.1443290"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1443290","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]},"article-number":"1443290"}}